Thrivent Financial for Lutherans Sells 93,804 Shares of Enovis Corporation $ENOV

Thrivent Financial for Lutherans cut its holdings in Enovis Corporation (NYSE:ENOV) by 43.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 119,825 shares of the company’s stock after selling 93,804 shares during the period. Thrivent Financial for Lutherans’ holdings in Enovis were worth $3,757,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ENOV. EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Enovis during the second quarter valued at approximately $46,000. CWM LLC lifted its stake in shares of Enovis by 564.9% in the 2nd quarter. CWM LLC now owns 3,790 shares of the company’s stock valued at $119,000 after purchasing an additional 3,220 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Enovis by 578.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,347 shares of the company’s stock worth $136,000 after purchasing an additional 3,706 shares during the period. Finally, McIlrath & Eck LLC increased its position in shares of Enovis by 52.2% during the 1st quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock valued at $202,000 after purchasing an additional 1,808 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ENOV shares. Wells Fargo & Company raised their price target on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Canaccord Genuity Group lowered their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.83.

Enovis Stock Performance

ENOV stock opened at $26.75 on Friday. Enovis Corporation has a twelve month low of $25.47 and a twelve month high of $49.38. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -1.13 and a beta of 1.52. The business’s fifty day simple moving average is $29.70 and its two-hundred day simple moving average is $30.35. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. The firm had revenue of $383.81 million for the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. Analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Transactions at Enovis

In other news, insider John Kleckner acquired 2,468 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were bought at an average price of $30.32 per share, with a total value of $74,829.76. Following the completion of the purchase, the insider directly owned 12,302 shares in the company, valued at $372,996.64. This trade represents a 25.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. Additional details regarding this sale are available in the official SEC disclosure. 2.70% of the stock is owned by corporate insiders.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.